CE mark for Abbott drug-eluting stent; Algeta targets hematological cancer;

> Abbott Laboratories ($ABT) has received a CE mark in Europe for its next-generation Xience Xpedition drug-eluting stent for a range of indications, including use with a minimum duration of three months of dual anti-platelet therapy (DAPT). This joins the family of Xience stents and uses a new stent delivery system. Article | Press release

> Algeta is developing a fourth targeted thorium conjugate (TTC) program, using an undisclosed monoclonal antibody to target the alpha-particle emitter thorium-227 to hematological cancer cells. Press release

> MIT researchers have developed nanoparticles that deliver RNA to mice to speed up the screening of new drug targets. Press release

> Pluristem Therapeutics has approval to begin a Phase II trial in India using its PLX cells. A multinational Phase III study in the U.S., Europe, and India is planned. Press release

> PCI Biotech is moving into bile duct cancer as the next indication for its PCI (photochemical internalization) localized cancer therapy. Press release

And Finally… Tailored nanoparticles latch onto blood platelets and create healthy clots, nearly doubling the survival rate in the vital first hour after injury. Press release